NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

Avicanna Inc. (AVCN.TO) Stock Analysis

Avicanna Inc. (AVCN.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

AVCN.TO

CA$0.13

+CA$0.01 (+8.33%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AVCN.TO with… →

AVCN.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$0.13
Previous Close
CA$0.12
Day's Range
0.12–0.13
52-Week Range
0.10–0.30
Volume
74.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.34
Valuation
Market Cap
CA$17.47M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.69
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.02
Financials (FY)
Revenue (FY)
CA$25.48M+0.08%
Net Income (FY)
−CA$2.84M
Profit marginThe share of revenue left as profit after all costs and taxes.
−14.75%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
134.38M
1-Year Return
−52.73%
Dividend and dates
Earnings Date
November 13, 2026estimated
Avg Volume
126.75K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AVCN.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−42.22%
2025−26.23%
2024−12.86%
2023−14.63%
2022−47.44%
2021−40.46%
2020−48.43%
2019 (partial year)−59.23%

As of September 4, 2026.

AVCN.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$25.48M−CA$2.84M−11.2%
2024CA$25.46M−CA$3.99M−15.7%
2023CA$16.79M−CA$8.74M−52.1%
2022CA$4.05M−CA$14.74M−364.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$25.48MCA$13.52M−CA$2.78M−CA$2.84M−11.2%
2024CA$25.46MCA$12.19M−CA$5.64M−CA$3.99M−15.7%
2023CA$16.79MCA$6.66M−CA$8.38M−CA$8.74M−52.1%
2022CA$4.05MCA$1.12M−CA$10.41M−CA$14.74M−364.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AVCN.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricAVCN.TODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.692.300.3x the median
Profit margin−14.75%−3.14%11.6 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Avicanna Inc. (AVCN.TO) at CA$17.47M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 112 employees.

Over the past 52 weeks the price has ranged from CA$0.10 to CA$0.30. The most recent close on file for AVCN.TO is CA$0.13, dated September 4, 2026. That is +CA$0.01 (+8.33%) against the previous close. The latest close sits 36.84% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to CA$25.48M. That is +0.08% against the prior fiscal year, when revenue was CA$25.46M. The same year closed with a net loss of CA$2.84M. Profit margin runs at −14.75%. That is 11.6 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −0.02.

Across the 4 fiscal years on file, revenue moves from CA$4.05M in 2022 to CA$25.48M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 0.69. On price-to-sales that is 0.3 times the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −52.73%. Measured over 5 years, that is −34.52% a year compounded. The reported beta is 0.35. Daily returns over the trailing 7 years annualize to a volatility of 95.21%.

Growth & Income

No dividend is on file for AVCN.TO.

Across the complete calendar years on file, 2024 returned −12.86% and 2020 returned −48.43%. Of the 6 complete calendar years on file, 0 finished higher. So far in 2026 the price is −42.22%.

Peer Comparison

Avicanna Inc. (AVCN.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Avicanna Inc. AVCN.TO CA$17.47M —
Takeda Pharmaceutical Company Limited TAK CA$58.92B —
Teva Pharmaceutical Industries Limited TEVA CA$42.37B 60.6
Haleon plc HLN CA$42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Avicanna Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Avicanna Inc.

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, as well as Trunerox, an indication-specific drug treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Visit website →